Alprafenone

Alprafenone

SCHEMBL1345342

CCC(C)(C)NCC(O)COc1cc(CCC(=O)c2ccc(C)cc2)ccc1OC

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 8/20 0.54
ADRB1 P08588 6/20 0.54
ADRB3 P13945 5/20 0.54
CASR P41180 5/20 0.48
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
SLC6A4 P31645 4/20 0.45
SLC6A3 Q01959 4/20 0.45
KCNH2 Q12809 4/20 0.45
HTR1A P08908 1/20 0.45
ADRA2C P18825 1/20 0.45
ADRA1A P35348 1/20 0.45
HTR2B P41595 1/20 0.45
CTNNB1 P35222 1/20 0.45
WNT3A P56704 1/20 0.45
SLC6A2 P23975 3/20 0.44
CYP2D6 P10635 2/20 0.44
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alprafenone SCHEMBL1231193 0.99 ADRB2 (0.53) ADRB2ADRB1ADRB3CASRKMT2A
SCHEMBL9815376 0.77 ADRB2 (0.53) ADRB2ADRB1ADRB3
SCHEMBL9815375 0.76 CASR (0.51) ADRB2ADRB1ADRB3CASRKMT2A
Hydrochloric Acid SCHEMBL9815343 0.76 ADRB2 (0.52) ADRB2ADRB1ADRB3
Hydrochloric Acid SCHEMBL9815374 0.76 CASR (0.50) ADRB2ADRB1ADRB3CASRKMT2A
SCHEMBL9815361 0.75 ABCB1 (0.56) ADRB2ADRB1ADRB3KMT2AMEN1
Hydrochloric Acid SCHEMBL9815342 0.74 KMT2A (0.56) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL8676380 0.73 MEN1 (0.53) ADRB2ADRB1CASRKMT2AMEN1
SCHEMBL11855803 0.73 CASR (0.70) ADRB2ADRB1ADRB3CASRSLC6A4
Diprafenone SCHEMBL563653 0.71 MEN1 (0.80) ADRB2ADRB1ADRB3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 CN claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 US claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-1999063984-A9 NOVEL SODIUM CHANNEL DRUGS AND USES 2002-04-25 WO claimed
EP-1085890-A1 NOVEL SODIUM CHANNEL DRUGS AND USES Advanced Medicine, Inc. (US) 2001-03-28 EP claimed
WO-1999063984-A1 NOVEL SODIUM CHANNEL DRUGS AND USES ADVANCED MEDICINE, INC. (US) 1999-12-16 WO claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 EP disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 EP disclosed
EP-0757558-A1 SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS ALZA CORPORATION (US) 1997-02-12 EP disclosed
WO-1995027510-A1 SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS ALZA CORPORATION (US) 1995-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA ADRB2 3813/4885ADRB1 3375/4885ADRB3 3450/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA ADRB2 3813/4885ADRB1 3375/4885ADRB3 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.